Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
Sponsor: AriBio Co., Ltd.
Listed as NCT03625622, this PHASE2 trial focuses on Mild to Moderate Alzheimer's Disease and remains completed. Sponsored by AriBio Co., Ltd., it has been updated 11 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
▶ Show 6 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Apr 2020 — Aug 2020 [monthly]
Recruiting PHASE2
-
May 2019 — Apr 2020 [monthly]
Recruiting PHASE2
-
Mar 2019 — May 2019 [monthly]
Recruiting PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2018 — Feb 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AriBio Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .